
LEY

Insights into the Epidemiology, Disease Burden, **Clinical Management, and Outcomes of Immune-Mediated Thrombotic Thrombocytopenic Purpura**

This infographic is intended for researchers and healthcare professionals and reflects the contents of the following article:


Adeyemi, A., Razakariasa, F., Chiorean, A., & de Passos Sousa, R. (2022). Epidemiology, Treatment Patterns, Clinical Outcomes, and Disease Burden Among Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura in the United States. Research and Practice in Thrombosis and Haemostasis, 6(6), e12802. DOI: 10.1002/rth2.12802



database-700 hospitals and 7,000 clinics in the **United States**



- than 10% or one or more iTTP episodes Age, gender, and index year
- 1:5-matched non-iTTP control cohort
- - Treatment patterns Clinical outcomes
 - Disease burden



Mean comorbidities per patient	iTTP: 14	Non-iTTP: 3	Disease burden					
Chronic kidney disease	47%	7%	Cluster analysis	Mean age	Mortality rate	Mean duration of index iTTP episode	>1 episode	Disease burden
Proteinuria	24%	1.45%				chicana		යිළු Kidney
End-stage renal disease	18%	0.5%	Older morbid patients with longer episodes	56 years	30%	19 days	13%	Pulmonary
Neurological signs and symptoms with altered mental status	39%	5%						Psychological
Stroke	39%	6%	Younger patients with comorbidities and short episodes	40 years	8%	13 days	64%	Cardiovascular
Dizziness/giddiness	55%	15%						
Speech and language difficulties	19%	2%	Younger less morbid patients with short episodes	43 years	4%	12 days	72%	Psychological
Tingling	41%	12%						
Cardiovascular diseases with arrhythmia	60%	15%						
Hypertension	70%	32%	Older very morbid patients with longer episodes	58 years	22%	20 days	29%	(දින්ති) Kidney මීම Pulmonary
Respiratory symptoms, such as dyspnoea	58%	16%						Cardiovascular

Key messages

Patients with iTTP are at an increased risk of morbidity and mortality, despite treatment with TPE and immunosuppressants. This highlights the need for more effective therapies

- Comorbidities reflect long-term organ damage, underscoring the importance of rapidly controlling ischaemia during iTTP episodes
- Clinical symptoms and disease burden worsen with age; analysing the sequence and pattern of comorbidities can aid in early detection and improve disease monitoring and management



Epidemiology, Treatment Patterns, Clinical Outcomes, and Disease Burden Among Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura in the United States Adeyemi *et al.* (2022) | *Research and Practice in Thrombosis and Haemostasis* | DOI: 10.1002/rth2.12802

